Frazier Healthcare Partners has launched a new biopharmaceutical company called Recida Therapeutics, which will develop new therapies for serious antibiotic-resistant infections, including Pseudomonas aeruginosa, the leading cause of lung infections in cystic fibrosis (CF) patients. RC-01 is Recida’s lead therapy candidate for multidrug-resistant Gram-negative bacteria, a group of…
News
Enrollment for a Phase 3 clinical trial testing AeroVanc in patients with cystic fibrosis with methicillin-resistant Staphylococcus aureus (MRSA) lung infections is expected to be completed in the third quarter of this year — between July and September. AeroVanc is an inhaled formulation of the antibiotic vancomycin hydrochloride being developed…
SQI Diagnostics announced two new research agreements with research hospital University Health Network (UHN), Toronto, Canada, to simplify the assessment of lungs for transplant. By creating and licensing multiplexed protein assays and point-of-care diagnostic strategies, they intend to improve the health of donor organs so they can be transplanted safely…
Somer Love is sitting at her favorite local hangout, the Landmark Grill in suburban Midvale, happily devouring her lunch. Looming on the horizon to the east are Utah’s majestic Wasatch Mountains, but at more than 10,000 feet above sea level, the range is strictly off-limits to Love — as is…
Cystic Fibrosis Canada — Calgary and Southern Alberta Chapter will hold the 30th Annual 65 Roses Ladies Golf Classic event on June 17 to raise funds and awareness for cystic fibrosis (CF). The automotive dealership Lexus of Calgary will present the event, to be held at the Earl Grey…
Patients with cystic fibrosis (CF) whose lungs have never been colonized by the Pseudomonas aeruginosa bacterium have a milder form of the disease, a retrospective study based on registry data suggests. The study, “Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French…
Health Canada has approved the use of Kalydeco (ivacaftor) in toddlers age 1-2 years with certain genetic mutations that prevent the correct functioning of the CFTR protein, the therapy’s developer announced. With a pill taken twice a day, Kalydeco, by Vertex Pharmaceuticals, makes it possible to resolve the underlying…
New personalized strategies that can address the nutritional needs of cystic fibrosis patients may provide the best care and improve patient outcomes, a study suggests. The study, “A survey identifying nutritional needs in a contemporary adult cystic fibrosis cohort,” was published in the journal BMC Nutrition.
The Cystic Fibrosis Foundation (CFF) will fund the preclinical development of two gene therapy candidates, Talee Bio’s TL-101 and TL-102, for the treatment of cystic fibrosis (CF), the company announced. Talee will receive up to $4.5 million from CFF to help accelerate the development of both these gene therapies…
The Horizon 2020 research and innovation program of the European Union granted €6.8 million (approximately $7.7 million) to an international research team for the development of non-viral gene delivery technology. This new gene therapy strategy has the potential to improve the health of patients with genetic diseases worldwide, including…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.